4 AACR Cancer Progress Report 2013
One-third of cancer
deaths are caused by
tobacco use ( 1).
1/3
One-third of cancer
diagnoses are related to
patients being overweight
or obese, physically
inactive, and consuming
a diet poor in nutritional
value ( 1).
1/3
New Drugs
Angiogenesis Inhibitors
Approved Indication Generic Name Trade Name Formulation
thyroid cancer cabozantinib Cometriq
colorectal cancer; gastrointestinal regorafenib Stivarga
stromal tumors
Cell Cytoskeleton Modifying Agents
Approved Indication Generic Name Trade Name Formulation
certain form of lung cancer* paclitaxel albumin- Abraxane
bound particles
Cell Signaling Inhibitors
Approved Indication Generic Name Trade Name Formulation
HER2+ breast cancer ado-trastuzumab Kadcyla
emtansine
certain type of lung cancer afatinib Gilotrif
certain type of leukemia bosutinib Bosulif
certain type of melanoma dabrafenib Tafinlar
certain type of bone cancer* denosumab Xgeva
certain types of leukemia ponatinib Iclusig
certain types of melanoma trametinib Mekinist
Immune System Modifiers
Approved Indication Generic Name Trade Name Formulation
certain type of lymphoma* lenalidomide Revlimid
multiple myeloma pomalidomide Pomalyst
Protein Translation Inhibitor
Approved Indication Generic Name Trade Name Formulation
certain type of leukemia omacetaxine Synribo
mepesuccinate
Radiation-emitting Drugs
Approved Indication Generic Name Trade Name Formulation
prostate cancer bone metastases radium Ra 223 dichloride Xofigo
New Technologies
Imaging Agents
Approved Indication/use Generic Name Trade Name Formulation
imaging dense breasts automated ultrasound Somo-v-ABUS
general imaging “low-dose, high- Aquilion ONE Vision
resolution CT scanner”
imaging lymphatics in breast cancer technetium Tc 99m Lymphoseek
and melanoma tilmanocept
Table 1: Newly FDA-approved Drugs, Indications, and Technologies for
the Treatment and Imaging of Cancer: Sept. 1, 2012-July 31, 2013
* New indication for 2013.
Where multiple trade names are used, only the most common have been listed.
